This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
TEIPP derived from non-mutant proteins may effectively target immune-edited tumors.
Why it matters
Understanding how to effectively target resistant tumors could lead to better cancer treatments. This research may help improve outcomes for patients who currently do not respond to existing therapies.
How the study worked
The study is a review of existing literature on cancer vaccines and immune checkpoint therapies.
What this study cannot tell us
As a review, it does not present new experimental data and relies on existing studies, which may vary in quality.
Read the original research
Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises.
Exploration of targeted anti-tumor therapy, 3(6), 746-762
Citation
Ashi, Mohamad Omar; Mami-Chouaib, Fathia; Corgnac, Stéphanie. (2022). Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises.. Exploration of targeted anti-tumor therapy, 3(6), 746-762. https://doi.org/10.37349/etat.2022.00111